top of page

Rhythm expands LG Chem bivamelagon obesity licence to $855 million and revises royalties

Writer: nuaxia
nuaxia
Nov 5
2 min read

Rhythm Pharmaceuticals has substantially expanded its existing bivamelagon licensing agreement with LG Chem, increasing potential deal consideration to $855 million while securing revised royalty economics across specified MC4R therapies.


The amendment announced on 2 November 2026 adds $350 million in fixed payments over four years and a potential $200 million milestone linked to $3 billion in annual global MC4R portfolio sales, raising the agreement's stated potential value from $305 million to $855 million.


In exchange, LG Chem's royalties change from low-to-mid-single-digit rates to 1% of global net sales across specified Rhythm MC4R agonists, while Rhythm's separately arranged term-loan facility of up to $750 million represents financing rather than consideration paid under the licence.

Field

Content

Article Type

Deals

Company

Rhythm Pharmaceuticals

Licensing Partner

LG Chem

Deal Type

Material amendment to existing exclusive licence agreement

Amendment Announcement Date

2 November 2026

Licensed Asset

Bivamelagon

Drug Class

Melanocortin-4 receptor agonist

Target

MC4R

Modality

Oral small-molecule therapeutic

Administration Route

Oral

Therapeutic Area

Rare obesity disorders

Development Status

Investigational

Original Potential Agreement Value

$305 million

Revised Potential Agreement Value

$855 million

Additional Fixed Payments

$350 million over four years

Additional Contingent Milestone

Up to $200 million

Milestone Trigger

$3 billion in annual global MC4R portfolio sales

Previous Royalty Structure

Low-to-mid-single-digit royalties

Revised Royalty Structure

1% of global net sales across specified Rhythm MC4R agonists

Royalty Scope

Specified MC4R agonists within Rhythm's portfolio

Separate Financing Arrangement

Term-loan facility providing access to up to $750 million

Financing Clarification

The term-loan facility is separate financing and is not licence consideration

Geographic Scope

Global sales referenced in the amended royalty and milestone terms

What Happened

Rhythm and LG Chem amended their existing bivamelagon licence to increase fixed and contingent payments while reducing specified royalty obligations.

Why It Matters

The amendment materially changes the economics of Rhythm's rare obesity portfolio by exchanging increased payment commitments for lower ongoing royalties.

Strategic Rationale

Improve long-term royalty economics across specified MC4R therapies while maintaining development rights to bivamelagon.

Financial Clarification

The $855 million represents the amended agreement's stated potential value, including contingent consideration, rather than an upfront payment.

Transaction Distinction

Amendment to an existing licence; not a newly acquired asset or regulatory approval.

Key Takeaway

Rhythm committed to additional fixed payments and a potential sales milestone in return for a revised 1% royalty structure.

What to Watch

Bivamelagon clinical development, MC4R portfolio sales, fixed payment schedules, milestone triggers and future financing needs.

Primary Source

Rhythm Pharmaceuticals

Primary Source URL

https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-and-lg-chem-enter-amendment-bivamelagon

Relevant Date

2 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page